Topic: Monoclonal antibodies

Develop antibody-based approaches to Alzheimer’s disease at the Queensland Brain Institute. The project investigates tau-targeting monoclonal antibodies through protein production, cell-based experiments and mouse studies. Responsibilities include analysing results, preparing publications, contributing to funding applications and supporting junior researchers. This full-time appointment runs for up to 12 months, with an immediate start preferred. Annual base pay is AUD 85,373–113,660, plus 17% superannuation.

Lifelong devotion to headache research has led to many discoveries. First a series of studies of brain blood flow during attacks of migraine. The results showed changes compatible with cortical spreading depression in migraine without aura effectively negating the then prevailing vasospastic/ischemic theory. In migraine without aura no changes in brain blood flow. This difference was crucial for the separation of migraine with aura and migraine without aura in the first and subsequent editions of the international headache classification headed by me. Then a human migraine provocation model th

One of the major challenges in developing therapeutics for the neurodegenerative disorders is the blood-brain barrier, limiting the availability of systemically administered therapies such as recombinant proteins or monoclonal antibodies from reaching the brain. Direct central nervous system (CNS) gene therapy using adeno-associated virus vectors expressing a therapeutic protein, monoclonal antibody or inhibiting RNA-coding sequences has two characteristics ideal for therapy of neurodegenerative disorders: circumventing the blood-brain barrier by directly expressing the therapy in the brain an